Document is current
Any future updates will be listed below
-
Authors
Husby, Simon https://orcid.org/0000-0002-6332-1173
Bæch-Laursen, Cecilie https://orcid.org/0000-0002-8526-1079
Eskelund, Christian W.
Favero, Francesco https://orcid.org/0000-0003-3684-2659
Jespersen, Jakob Schmidt https://orcid.org/0000-0002-4930-5900
Hutchings, Martin
Pedersen, Lone Bredo
Niemann, Carsten U. https://orcid.org/0000-0001-9880-5242
Weischenfeldt, Joachim https://orcid.org/0000-0002-3917-5524
Räty, Riikka
Larsen, Thomas Stauffer https://orcid.org/0000-0002-8418-6708
Kolstad, Arne
Jerkeman, Mats https://orcid.org/0000-0003-4509-6707
Grønbæk, Kirsten https://orcid.org/0000-0002-1535-9601
-
Funding
Funding for this research was provided by:
Kræftens Bekæmpelse (0001)
- License Information
-
More Information
Article History
Received: 17 June 2022
Revised: 1 September 2022
Accepted: 4 October 2022
First Online: 23 October 2022
Competing interests
: TSL: Research Support: Roche. Advisory Board: Roche, Novartis, Gilead and BMS. CUN: Research support, consultancy fees, or travel grants from Abbvie, Gilead, Janssen, Roche, CSL. MH: Consulting or Advisory Role: Takeda, Roche, Genmab. Research Funding: Celgene, Genmab, Roche, Takeda, Novartis.
